Navigation Links
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Date:2/7/2008

d HIV-1 strains resistant to a NNRTI and other ARV agents.

This indication is based on Week 24 analyses from two randomized, double- blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

-- Treatment history and, when available, resistance testing, should guide

the use of INTELENCE.

-- The use of other active antiretroviral agents with INTELENCE is

associated with an increased likelihood of treatment response.

-- In patients who have experienced virologic failure on an

NNRTI-containing regimen, do not use INTELENCE in combination with

only N[t]RTIs.

-- The risks and benefits of INTELENCE have not been established in

pediatric patients or in treatment-nave adult patients.

DUET-1 and -2 Study Design

The DUET-1 and -2 studies, identical in design but conducted in different regions, assessed the 24- and 48-week efficacy and safety of INTELENCE in combination with a BR in treatment-experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. The primary endpoint was the proportion of patients who achieved a confirmed undetectable viral load (less than 50 copies/mL)

Patients with HIV-1 who were eligible for the DUET studies had a viral load of greater than 5,000 copies/mL while on a stable antiretroviral therapy regimen for at least eight weeks and had evidence of at least one NNRTI- resistance-associated mutation, either at screening or from prior resistance tests, as well as evidence of three or more primary PI mutations (D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M) at screening.

Participants in the DUET studies were randomized to receive INTELENCE 200 mg twice daily (599 patients) or pl
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
3. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
6. Vanda Presents Phase III Iloperidone Efficacy Data
7. Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
8. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
11. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... announce that TUV-SUD and The Medicinal Evaluation Board ... has granted its request for a label expansion ... initially approved in July 2013 for use in ...
(Date:9/22/2014)... PLEASANTON, Calif. , Sept. 22, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... D. Keith Grossman has been appointed President and ... F. Burbach , who has stepped down from his ... advisor to the company through the first quarter of ...
(Date:9/22/2014)... Sept. 22, 2014 Auxilium Pharmaceuticals, Inc. ... company, today announced that its Board of Directors ... conditional proposal from Endo International plc ("Endo") and, ... advisors, has unanimously determined it is not a ... merger agreement with QLT Inc. ("QLT") and has ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... Based on its recent analysis of the ... Hybridyne Technologies, Inc. with the 2010 North American ... the Year. (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ... ProxiScan™, recently approved by the FDA, is ...
... Upstate New York Laboratory Robotics Interest Group (LRIG) ... Society of Mechanical Engineers (ASME) will be hosting ... 27, 2010 entitled "Unconventional High-Throughput Applications," featuring Pankaj ... Seth Cohen, Ph.D., Senior Director Microfluidics Applications, Caliper ...
Cached Medicine Technology:Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 2Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 3Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 4Upstate New York Laboratory Robotics Interest Group (LRIG) to Host Free Symposium and Exhibition 2
(Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , ... for hip bursitis treatment in Manhattan. This treatment is now offered ... bursitis, which is also called trochanteric bursitis, occurs when ... is a fluid-filled sac in the hip, between the ...
(Date:9/22/2014)... eye transplant seems futuristic, if not impossible. But ... of Defense, researchers at University of California, San ... implantation of an entire, functional eye a reality. ... holy grail for vision restoration," said Jeffrey Goldberg, ... with colleagues at University of Pittsburg Medical Center ...
(Date:9/22/2014)... 22, 2014 This Flash Report is ... management needs for the Prostate Cancer market. , Download ... stakeholder strategies for any launching Prostate Cancer product:, ... within an increasingly crowded market , Understanding ... of identifying community-based thought leaders and stakeholders ,Download ...
(Date:9/22/2014)... The Workgroup for Electronic ... authority on the use of health IT to ... from its recent industry survey on the use ... electronic transactions adopted under the Health Insurance Portability ... from August 20 to September 5, which included ...
(Date:9/22/2014)... CareFlight Air & Mobile Services of ... AS365 N3+ Dauphin, the latest version of Airbus Helicopters ... based at Miami Valley Hospital in Dayton, ... transport helicopters. , “We have a lot of confidence ... President, Emergency, Trauma, and CareFlight. “We’ve been operating Dauphins ...
Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... released new clinical guidelines for the treatment of exacerbations ... literature on current clinical practices. "This is the ... practices for pulmonary exacerbation of cystic fibrosis," said Susanna ... and director of the Cystic Fibrosis Center at Children,s ...
... N.C. Studies by researchers at Wake Forest University ... receptor in immature rats leads to profound, rapid brain ... mature. The N-methyl-D-aspartate (NMDA) receptor is activated ... released by brain cells. This allows calcium to enter ...
... at-risk American adults who would benefit from vaccination against seasonal ... believe they do not need them and are not inclined ... intend to take up the vaccine, nearly half get around ... Corporation* in Arlington, USA, and her team. Their work (1) ...
... prescriptions issued by GPs has been caused by a year ... drugs on a long-term basis, according to researchers from the ... printed edition of British Medical Journal ( BMJ ... number of new patients diagnosed with depression over 11 years, ...
... chance of success , THURSDAY, Oct. 22 (HealthDay News) -- ... offer the best chance of success with in vitro fertilization ... selecting embryos for implantation in the mother,s womb is highly ... IVF failure or multiple pregnancies," Dr. Emre Seli, an associate ...
... medication leads to better outcome, researchers say , ... say they have a better treatment for patients ... standard therapy. , Their study finds that treatment ... better short-term survival and with lower toxicity than ...
Cached Medicine News:Health News:New clinical guidelines for exacerbations in cystic fibrosis 2Health News:General anesthetics lead to learning disabilities in animal models 2Health News:General anesthetics lead to learning disabilities in animal models 3Health News:Flu shots not to be sneezed at 2Health News:Assessing Embryo Metabolism May Aid IVF Success 2Health News:Study Finds Less Toxic Treatment for Myeloma 2
... USAs Large Bone Power System is a ... technological advancements. The truly innovative design features ... which is comprised of the battery, motor ... only mechanical components, which provides a truly ...
... ApaPore is a synthetic ... is disease free, readily ... a highly controlled specification ... graft., ,Surgical applications include ...
... ART Aerosol Resistant Tips offer a safe ... Tips are designed for applications such as ... In addition, ART Tips are excellent for ... forensic studies. ART Tips prevent aerosol contaminants ...
... orifice tip, the Finntip Wide is designed ... macromolecules like genomic DNA. This tip eliminates ... It is excellent for use with extremely ... inside diameter of the orifice is 1.1 ...
Medicine Products: